특허 및 연구성과

This study investigates the intricate relationship between excessive adipocyte production, leading to Type 2 Diabetes (T2D) and chronic inflammation characterized by elevated reactive oxygen species (ROS) and nitric oxide (NO) levels. Leveraging in silico studies, computational analyses unravel the interaction between major compounds of Kakadu Plum (KKD-NT) including ellagic acid (EA), gallic acid (GA), daidzin (DD), and ascorbic acid (AA) with pivotal obesity-related biomolecules (PPARγ, C/EBPα, β-catenin). Notably, EA and DD display a superior binding affinity with active residues compared to GA, AA, and the control drug Resveratrol (RSV). Experimental validation showcases the capacity of KKD-NT to diminish intracellular ROS in hypertrophied adipocytes by amplifying antioxidant defense enzymes (SOD, Catalase, GPx). KKD-NT further mitigates obesity-induced inflammation by reducing lipid accumulation, NO production, influencing adipogenesis factors (PPARγ, CEBPɑ, and FAS), Wnt signaling (β-catenin), and pro-inflammatory mediators (TNF-ɑ, IL-6, leptin) in 3T3-L1 cells. In vitro evaluations attest to anti-diabetic properties of KKD-NT as evidenced by enhancing glucose uptake and inhibiting α-glucosidase activity. The up-regulation of GLUT4 and adiponectin mRNA expression suggests potential benefits for obesity and diabetes. While acknowledging the need for further research to assess safety and in vivo effectiveness, this study suggests that KKD-NT and its bioactive components hold promise as innovative therapeutic interventions for obesity and related metabolic diseases, opening avenues for future exploration in clinical applications.